Results for tag: "Roxadustat"

Roxadustat is a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by FibroGen and AstraZeneca for the treatment of anemia associated with chronic kidney disease (CKD). It is the first HIF-PHI to be approved by the US Food and Drug Administration (FDA) for the treatment of anemia in CKD patients on dialysis and not on dialysis. Roxadustat is a hematological drug that works by stimulating the production of red blood cells, which helps to improve oxygen delivery to tissues and organs. It is also being studied for its potential to treat anemia associated with myelodysplastic syndromes (MDS). Roxadustat is part of a growing market of hematological drugs, which includes other HIF-PHIs, erythropoiesis-stimulating agents (ESAs), and immunomodulatory drugs (IMiDs). These drugs are used to treat a variety of hematological conditions, including anemia, myelodysplastic syndromes, and multiple myeloma. Companies in the Roxadustat market include FibroGen, AstraZeneca, Amgen, Celgene, and Novartis. Show Less Read more